I am a Healthcare Professional

These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.

Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.

Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.

Reject

ACAAI 2024 Sanofi | Regeneron | Oct 24, 2024 - Oct 28, 2024

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1

  • Asthma

    Asthma is predominately a chronic type 2 inflammatory disease. When uncontrolled, asthma is characterized by impaired lung function, severe exacerbations, recurrent symptoms, and poor quality of life.

  • Atopic Dermatitis

    Atopic dermatitis is a chronic, predominantly type 2 inflammatory disease characterized by intense itch, skin lesions, and increased risk of infections, barrier dysfunction, and poor quality of life.

  • CRSwNP

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease characterized, when uncontrolled, by bilateral nasal polyps, congestion, and impaired sense of smell, that is associated with persistent symptoms and poor quality of life.

  • EoE

    Eosinophilic Esophagitis (EoE) is a chronic type 2 inflammatory disease characterized by specific histologic changes, dysphagia, and poor quality of life due to esophageal scarring and narrowing.